Skip to main content

Table 4 Virologic failure risk analyzed with bivariate and adjusted HRs of Cox proportional hazards frailty model

From: Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam

  Bivariate Adjusted
Characteristics HR (95% CI) p-value aHR (95% CI) p-value
Intervention group 1.0 (0.5;1.7) 0.94   
Male gender 2.0 (0.1;4.0) 0.05   
Age <35 years 0.7 (0.4;1.4) 0.37   
Severe HIV (clinical stage 3 or 4) 1.2 (0.6;2.1) 0.59   
History of IDU 1.9 (1.0;3.3) 0.04   
ART-non-naïve status 4.8 (2.4;9.4) <0.01 7.0 (3.3–14.7) <0.01
TB history 1.6 (0.8;3.2) 0.15   
VL at baseline ≥100,000 copies/ml 1.6 (0.9;2.8) 0.13 2.3 (1.2–4.3) <0.05
CD4 at baseline < 100 cells/μl 1.4 (0.8;2.5) 0.28   
Having an HIV-infected family member 0.5 (0.3;0.9) 0.03   
From Ha long OPC 1.0 (0.6;1.8) 0.91   
History of OIs 0.5 (0.2;1.0) 0.06   
Changed ART regimen 1.1 (0.5;−2.0) 0.85   
Incomplete adherence 2.4 (0.9;6.7) 0.09 3.1 (1.1–8.9) <0.05
  1. OIs opportunistic infections, VL viral load, IDU Injecting drug use, TB tuberculosis, ART Antiretroviral therapy, OPC outpatient clinic, HR Hazard Ratio, aHR adjusted Hazard Ratio
  2. The boldface indicates significant (p<0,05) result